FDA announcement on approval of Kymriah CAR T therapy from Novartis. Historic announcement: First gene therapy to be approved in the US. FDA announcement: read here
"The safety and efficacy of Kymriah were demonstrated in one multicenter clinical trial of 63 pediatric and young adult patients with relapsed or refractory B-cell precursor ALL. The overall remission rate within three months of treatment was 83 percent."
And from Novartis' announcement:
"This therapy is a significant step forward in individualized cancer treatment that may have a tremendous impact on patients' lives," said Carl June, MD, the Richard W. Vague Professor of Immunotherapy, Director of the Center for Cellular Immunotherapies in Penn's Perelman School of Medicine, who is a pioneer of this new treatment.
Note: my August 30 original post had a mistake in it. I referenced a section in the FDA announcement that referred to Actemra instead of Kymriah. I have corrected the post.